Equities researchers at Royal Bank Of Canada initiated coverage on shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) in a note issued to investors on Thursday, The Fly reports. The firm set an “outperform” rating on the stock.

Several other equities research analysts have also recently commented on KPTI. ValuEngine cut shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 25th. Cantor Fitzgerald set a $18.00 price target on shares of Karyopharm Therapeutics and gave the stock a “buy” rating in a research report on Saturday, June 24th. Robert W. Baird reiterated an “outperform” rating and set a $15.00 price target on shares of Karyopharm Therapeutics in a research report on Tuesday, July 4th. Zacks Investment Research raised shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a research note on Thursday, July 6th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $16.00 price objective on shares of Karyopharm Therapeutics in a research note on Friday, July 14th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the stock. Karyopharm Therapeutics has a consensus rating of “Buy” and a consensus price target of $15.88.

Shares of Karyopharm Therapeutics (NASDAQ:KPTI) traded down 0.19% during midday trading on Thursday, hitting $10.57. 105,144 shares of the company traded hands. The stock’s 50-day moving average is $9.14 and its 200 day moving average is $9.86. Karyopharm Therapeutics has a 12-month low of $6.27 and a 12-month high of $14.63. The stock’s market capitalization is $498.25 million.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Tuesday, August 8th. The company reported ($0.64) EPS for the quarter, hitting the consensus estimate of ($0.64). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 70.42%. During the same quarter in the previous year, the business posted ($0.84) earnings per share. The business’s quarterly revenue was down 95.0% compared to the same quarter last year. On average, analysts expect that Karyopharm Therapeutics will post ($2.68) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Karyopharm Therapeutics Inc. (KPTI) Coverage Initiated at Royal Bank Of Canada” was first posted by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/09/14/karyopharm-therapeutics-inc-kpti-coverage-initiated-at-royal-bank-of-canada.html.

A number of institutional investors have recently added to or reduced their stakes in KPTI. Teachers Advisors LLC boosted its stake in Karyopharm Therapeutics by 15.0% during the 4th quarter. Teachers Advisors LLC now owns 41,436 shares of the company’s stock worth $389,000 after acquiring an additional 5,419 shares during the last quarter. Nationwide Fund Advisors boosted its stake in Karyopharm Therapeutics by 175.8% during the 1st quarter. Nationwide Fund Advisors now owns 56,527 shares of the company’s stock worth $726,000 after acquiring an additional 36,031 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in Karyopharm Therapeutics by 103.9% during the 1st quarter. Russell Investments Group Ltd. now owns 74,882 shares of the company’s stock worth $962,000 after acquiring an additional 38,158 shares during the last quarter. Wells Fargo & Company MN boosted its stake in Karyopharm Therapeutics by 114.6% during the 1st quarter. Wells Fargo & Company MN now owns 43,606 shares of the company’s stock worth $560,000 after acquiring an additional 23,284 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Karyopharm Therapeutics by 61.7% during the 1st quarter. Bank of New York Mellon Corp now owns 181,602 shares of the company’s stock worth $2,332,000 after acquiring an additional 69,315 shares during the last quarter. 58.97% of the stock is currently owned by institutional investors and hedge funds.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

The Fly

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.